Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 248

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 248
---
 1, 2025 and (ii) 246,807 additional shares of common stock that may be issued pursuant to our 2021 ESPP pursuant to an annual increase effective on January 1, 2025. |

| (5) | Reflects (i) an option to acquire 490,000 shares at an exercise price per share equal to $4.30 issued                                                                                                   
 under the 2023 Plan and (ii) warrants issued for the purchase of 29,167 shares of common stock at an exercise price of $7.29 per share. These warrants are compensatory in nature and are fully vested. |

- 175 -

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS The following is a description of each transaction since January 1, 2023, and each currently proposed transaction, in which we were a party and in which:

| • |     | the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and |

| • |     | any of our directors (including director nominees), executive officers, or beneficial holders of more than 5% of                                                                                            
 any class of our voting securities, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. |

PIPE Financing and Subscription Agreement On December 19, 2024, we entered into the Subscription Agreement with each of the PIPE Investors, pursuant to which we agreed to sell to the PIPE Investors (i) 21,592,000 shares of our common stock, par, at a purchase price of $2.40 per share, and (ii) 20,076,500 Pre-Funded Warrants to acquire common stock, at a purchase price of $2.3999 per Pre-FundedWarrant, for an aggregate purchase price of $100 million (collectively, the “PIPE Financing”). The Pre-FundedWarrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable, and remain exercisable until exercised in full. The holders of Pre-FundedWarrants may not exercise a Pre-FundedWarrant if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99%, at the election of the holder, of the number of shares of common stock outstanding immediately after